Jordana Jampel

DocwireNews

In head and neck cancer (HNC), various cortisol indices are known to correlate with adverse phycological and biologic (eg, inflammatory) outcomes, but links to mortality rate has not been investigated. A research group led by Elizabeth Cash conducted a study to hypothesize that the prognostic value of diurnal cortisol aberrations will hold in HNC.
The results, <a href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1436996/full" target="_blank" rel="noopener">published</a> in Frontiers in Oncology, builds on prior work that led the research team to predict that flattened or elevated diurnal cortisol profiles will be associated with elevations of serum inflammatory and tumor-promoting cytokines in this population and that these immune markers would predict poor progression-free survival.
A pilot sample of 40 patients with HNC were recruited; most presented with late-stage oral/oropharyngeal cancer, were older than 50 years, were men, and subsequently received combined-modality (surgery and/or radiotherapy with or without chemotherapy) treatment with curative intent.
Saliva was collected twice daily for six days to assess diurnal slope, mean, waking, and evening cortisol levels. Serum assays were performed for an exploratory panel of inflammatory and tumor-promoting cytokines. Two years after entering the study, disease progression and survivorship status were abstracted from medical records for the participants.
Bivariate correlations, linear regressions, and Cox proportional hazards models were used to test the hypothesis that disrupted diurnal cortisol rhythms would be associated with poorer two-year progression-free survival.
Elevations of evening cortisol and diurnal mean levels were each associated with shorter progression-free survival (evening: hazard ratio [HR], 1.848; 95% CI, 1.057-3.231; P=.031; diurnal mean: HR, 2.662; 95% CI, 1.115-6.355; P=.027). Bivariate correlations revealed that higher levels of the serum inflammatory marker interferon (IFN)-γ were linked with elevated evening (r=.405; P=.014) and mean (r=.459; P=.004) cortisol. Higher expression of IFN-γ also predicted poorer progression-free survival (HR, 4.67; 95% CI, 1.409-15.484; P=.012).
According to the research group, the results suggest that cortisol secretion is both dysregulated and elevated among patients who subsequently experienced accelerated HNC disease progression. These data from the 40 patients with HNC mirror relationships between cortisol levels and survival identified among patients with various other tumor types.
“This pilot study highlights the need for research on effects of cortisol rhythm disruption among HNC patients. Future research in larger samples should also examine the role of inflammatory and tumor-promoting factors-both systemically and within the tumor microenvironment-as potential mediators of cortisol rhythm disruption,” the researchers concluded.
Source
<a href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1436996/full">Evening cortisol levels are prognostic for progression-free survival in a prospective pilot study of head and neck cancer patients.</a>

Laura Litwin

How is New-Onset Atrial Fibrillation in Black Patients Connected to Resting Heart Rate?

Atrial Fibrillation

Rob Dillard

Assessing Axillary Pathologic Complete Response in Triple-Negative Breast Cancer

SABCS 2024

Transthyretin Tetramer Destabilization Associated With All-Cause Mortality in Danish Population Study

Preventive Cardiology

Latest News

Accelerated Disease Progression in Head, Neck Cancers Correlates With Cortisol Rhythm Disruption

Head and Neck Cancer

The researchers hypothesized that the prognostic value of diurnal cortisol aberrations will hold in HNC. 

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe